Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HSK39004 Suspension in Healthy Volunteers and COPD Patients
NCT06905847Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HSK39004 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Adverse Events. Started Sep 2024; status: completed.
02
Drugs
HSK39004
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06905847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905847.